Alpha 2.0
Login Register
» Articles » PMID: 36352205

Teclistamab: First Approval

Overview
Journal Drugs
Specialty Pharmacology
Date 2022 Nov 9
PMID 36352205
Authors
Connie Kang
Affiliations
Soon will be listed here.
Abstract

Teclistamab (TECVAYLI), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and Development for the treatment of relapsed or refractory multiple myeloma. Teclistamab was recently granted conditional approval in the EU for the treatment of adult patients with relapsed and refractory multiple myeloma who have received three or more prior therapies (including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody) and have demonstrated disease progression on the last therapy. Teclistamab was subsequently approved in the US for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody). This article summarizes the milestones in the development of teclistamab leading to this first approval for relapsed or refractory multiple myeloma.

Citing Articles

Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.

Sorgiovanni I, Del Giudice M, Galimberti S, Buda G Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005960 PMC: 11859432. DOI: 10.3390/ph18020145.

Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy.

Middelburg J, Schaap G, Sluijter M, Lloyd K, Ovcinnikovs V, Schuurman J J Immunother Cancer. 2025; 13(1.

PMID: 39800374 PMC: 11749218. DOI: 10.1136/jitc-2024-010331.

Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies.

Jureczek J, Kalwak K, Dziegiel P Cancers (Basel). 2025; 16(24.

PMID: 39766080 PMC: 11674729. DOI: 10.3390/cancers16244181.

Teclistamab as an Effective Treatment for Pericardial Effusion in Relapsed Multiple Myeloma: Case Report and a Brief Literature Review.

Bandaru S, Multani N, Nauam W, Benitez-Farina C Case Rep Oncol. 2024; 17(1):1063-1069.

PMID: 39474547 PMC: 11521517. DOI: 10.1159/000540979.

Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies.

Choi S, Lee J, Ko S, Hong S, Jin H Biomol Ther (Seoul). 2024; 32(6):708-722.

PMID: 39448393 PMC: 11535297. DOI: 10.4062/biomolther.2024.146.

References
1.
Pont M, Hill T, Cole G, Abbott J, Kelliher J, Salter A . γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019; 134(19):1585-1597. PMC: 6871311. DOI: 10.1182/blood.2019000050. View
2.
Usmani S, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021; 398(10301):665-674. DOI: 10.1016/S0140-6736(21)01338-6. View
3.
Moreau P, van de Donk N, Delforge M, Einsele H, De Stefano V, Perrot A . Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma. Adv Ther. 2023; 40(5):2412-2425. PMC: 10129954. DOI: 10.1007/s12325-023-02480-7. View
4.
Girgis S, Wang Lin S, Pillarisetti K, Verona R, Vieyra D, Casneuf T . Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma. Blood Adv. 2022; 7(4):644-648. PMC: 9979748. DOI: 10.1182/bloodadvances.2022007625. View
5.
Girgis S, Wang Lin S, Pillarisetti K, Banerjee A, Stephenson T, Ma X . Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma. Target Oncol. 2022; 17(4):433-439. PMC: 9345835. DOI: 10.1007/s11523-022-00893-y. View